Senores Pharmaceuticals L
NSE: SENORES · Pharmaceuticals · sector
₹1,245.50NSE close 2026-10-26
Key numbers
Market cap₹5,736 cr
Price₹1,245.50
52w high / low₹1,599 / ₹706
P/E43.9xSector median 27.9x
P/B6.1xSector median 2.9x
Book value₹202.7
Dividend yield–Sector median 0.48%
ROE15.3%Sector median 11.7%
ROCE15.8%Sector median 12.3%
OPM29.6%Sector median 14.0%
Debt / equity0.35xSector median 0.16x
EV/EBITDA28.8xSector median 18.6x
Interest cover7.3x
Current ratio1.92x
Sales growth 3y–Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹160 cr vs borrowings ₹327 cr (FY26): borrowings are higher by ₹167 cr.
- Operating profit covered interest 7.3x in the last 12 months.
- 2.81% of the promoters' shares are pledged (1.3% of all shares).
- Other income was 23% of net profit in the last 12 months.
- No dividend in the last 2 financial years.
- Price ₹1,245.50 on 2026-10-26: -22.1% from the 52-week high, +76.4% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹1,550.90 · low ₹495.00
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | 103 | 114 | 138 | 162 | 175 | 175 | 180 |
| EBITDA | 26 | 19 | 34 | 50 | 54 | 47 | 54 |
| OPM % | 24.9% | 17.0% | 24.8% | 30.6% | 30.9% | 27.1% | 29.8% |
| Other income | 5 | 12 | 3 | 5 | 4 | 18 | 3 |
| Net profit | 17 | 18 | 20 | 32 | 32 | 37 | 31 |
| EPS (₹) | 5.04 | 3.81 | 4.60 | 6.54 | 7.29 | 7.96 | 6.61 |
| Revenue YoY | +69.4% | +53.4% | +30.6% | ||||
| Profit YoY | +84.3% | +104.1% | +55.7% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY25 | FY26 | TTM |
|---|---|---|---|
| Revenue | 398 | 633 | 692 |
| EBITDA | 90 | 168 | 205 |
| Net profit | 58 | 122 | 131 |
| EPS (₹) | 16.12 | 26.39 | 28.40 |
| Revenue growth | +58.9% | – | |
| Profit growth | +108.3% | – | |
| Dividend / share (₹) | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | – | – | – |
| Net profit | – | – | – |
| EPS | – | – | – |
| Share price | – | – (2y) | +63.2% |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 786 | 934 |
| Borrowings | 305 | 327 |
| Cash & equivalents | 386 | 160 |
| Total assets | 1,227 | 1,604 |
| Fixed assets | 199 | 331 |
| Capital work in progress | 44 | 17 |
| Investments | 0 | 4 |
| Receivables | 124 | 325 |
| Inventory | 57 | 89 |
| Payables | 67 | 235 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | -46 | 62 |
| Cash from investing | -429 | -121 |
| Cash from financing | 573 | -1 |
| Capex | 158 | 240 |
| Free cash flow | -203 | -178 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | 7.4% | 13.0% |
| ROCE % | 8.4% | 14.6% |
| Debtor days | 114 | 187 |
| Inventory days | 114 | 130 |
| Payable days | 136 | 340 |
| Cash conversion cycle (days) | 92 | -23 |
| Working capital days | 442 | 224 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 45.82% |
| FIIs | 6.01% |
| DIIs | 10.84% |
| of which Mutual funds | 7.36% |
| of which Insurance | 1.28% |
| Public (non-institutions) | 37.33% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 45.76% | 45.77% | 45.78% | 45.80% | 45.80% | 45.82% | 45.82% | 45.82% |
| Promoter group | % |
|---|---|
| Swapnil Jatin Shah | 7.72% |
| Ashokbhai Vijaysinh Barot | 7.55% |
| Remus Pharmaceuticals Limited | 7.08% |
| Renosen Pharmaceuticals Private Limited | 5.90% |
| Anar Swapnil Shah | 4.98% |
| Aviraj Overseas LLC | 4.12% |
| Sangeeta Mukur Barot | 2.26% |
| Aviraj Group LLC | 1.49% |
| Espee Therapeutics LLP | 1.07% |
| Jitendra Babulal Sanghvi | 1.06% |
| Mukur Yogeshkumar Barot | 0.99% |
| Shantaben Babulal Sanghvi | 0.71% |
| Dhananjay Ashokkumar Barot | 0.61% |
| Hemant Ishwarlal Modi | 0.13% |
| Pinky Jatin Shah | 0.07% |
| Public holders above 1% | % |
|---|---|
| HSBC Mutual Fund - HSBC Multi CAP Fund | 2.87% |
| Manoj Prakash Sanghvi | 1.86% |
| Ratnamani Marketing Private Limited | 1.82% |
| Bajaj Finserv Flexi CAP Fund | 1.79% |
| Astorne Capital VCC - Arven | 1.36% |
| Aditya Birla SUN Life Insurance Company Limited | 1.28% |
| Trustmf Small CAP Fund | 1.23% |
| Jayanti Mishrimal Sanghvi . | 1.23% |
| Mahindra Manulife Innovation Opportunities Fund | 1.21% |
| Jigar Prakash Sanghvi | 1.19% |
| Prakash Mishrimal Sanghvi | 1.03% |
42,642 shareholders. Pledged: 2.81% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| SENORES | ₹5,736 cr | 43.9x | 6.1x | 15.3% | 15.8% | 29.6% | – | – |
Documents
- Annual report FY26
- Annual report FY26
- Annual report FY25
- Annual report FY25
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Research & Development, Manufacturing, Marketing, and Distribution of Pharmaceutical Products: Manufacturing and sale of pharmaceutical products
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | SENORES |
| BSE code | 544319 |
| ISIN | INE0RB801010 |
| Face value | ₹10.0 |
| Incorporated | 2017-12-26 |
| Website | www.senorespharma.com |
| Plants (India / abroad) | 2 / 0 |
From the company's filings (BRSR FY26).
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.